Antibodies to human IL-17F and other CTLA-8-related proteins and methods related thereto

Abstract

Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 and related proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.

1 - 7 . (canceled)  
     
     
         8 . An isolated human CTLA-8 protein comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:2;    (b) the amino acid sequence of SEQ ID NO:2 from amino acids 11 to 163;    (c) the amino acid sequence of SEQ ID NO:2 from amino acids 29 to 163;    (d) the amino acid sequence of SEQ ID NO:2 from amino acids 31 to 163; and    (e) fragments of (a), (b), (c) or (d) having CTLA-8 activity.    
     
     
         9 - 10 . (canceled)  
     
     
         11 . A pharmaceutical composition comprising a human CTLA-8 protein of  claim 8  and a pharmaceutically acceptable carrier.  
     
     
         12 - 13 . (canceled)  
     
     
         14 . A method of treating a mammalian subject comprising administering a therapeutically effective amount of a composition of  claim 11 .  
     
     
         15 . A method of treating a mammalian subject comprising administering a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:4;    (b) the amino acid sequence of SEQ ID NO:4 from amino acids 18 to 150; and    (c) the fragments of (a) or (b) having CTLA-8 activity.    
     
     
         16 . The method of  claim 15  wherein said protein comprises the amino acid sequence of SEQ ID NO:4.  
     
     
         17 . The method of  claim 15  wherein said protein comprises the amino acid sequence of SEQ ID NO:4 from amino acids 18 to 150.  
     
     
         18 . A method of treating a mammalian subject by administering a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:6;    (b) the amino acid sequence of SEQ ID NO:6 from amino acids 19 to 151; and    (c) fragments of (a) or (b) having CTLA-8 activity.    
     
     
         19 . The method of  claim 18  wherein said protein comprises the amino acid sequence of SEQ ID NO:6.  
     
     
         20 . The method of  claim 18  wherein said protein comprises the amino acid sequence of SEQ ID NO:6 from amino acids 19 to 151.  
     
     
         21 - 22 . (canceled)  
     
     
         23 . A method of treating a mammalian subject comprising administering a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and IL-17 or an active fragment thereto.  
     
     
         24 . The method of  claim 14 ,  15 ,  18  or  23  wherein said subject is treated to produce an effect selected from the group consisting of inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumor growth, inhibition of angiogenesis-dependent tissue growth, proliferation of myeloid cells or progenitors, proliferation of erythroid cells or progenitors, proliferation of lymphoid cells or progenitors, induction of IFNγ production, induction of IL-3 production and induction of GM-CSF production.  
     
     
         25 - 27 . (canceled)  
     
     
         28 . A method of treating a subject with an autoimmune disorder, the method comprising administering to the subject an antibody that specifically reacts with a protein comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:2;    (b) the amino acid sequence of SEQ ID NO:2 from amino acids 11 to 163;    (c) the amino acid sequence of SEQ ID NO:2 from amino acids 29 to 163;    (d) the amino acid sequence of SEQ ID NO:2 from amino acids 31 to 163; and    (e) a fragment of the amino acid sequence of SEQ ID NO:2 having at least one CTLA-8 activity selected from the group consisting of induction of expression or secretion of γ-IFN, induction of expression or secretion of IL-6, induction of expression or secretion of IL-8, and inhibition of angiogenesis.    
     
     
         29 . The method of  claim 28 , wherein the autoimmune disorder is rheumatoid arthritis or inflammatory bowel disease.  
     
     
         30 . A method of treating a subject with a condition selected from the group consisting of asthma and related respiratory conditions, the method comprising administering to the subject an antibody that specifically reacts with a protein comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:2;    (b) the amino acid sequence of SEQ ID NO:2 from amino acids 11 to 163;    (c) the amino acid sequence of SEQ ID NO:2 from amino acids 29 to 163;    (d) the amino acid sequence of SEQ ID NO:2 from amino acids 31 to 163; and    (e) a fragment of the amino acid sequence of SEQ ID NO:2 having at least one CTLA-8 activity selected from the group consisting of induction of expression or secretion of γ-IFN, induction of expression or secretion of IL-6, induction of expression or secretion of IL-8, and inhibition of angiogenesis.    
     
     
         31 . The method of  claim 30 , wherein the condition is asthma.